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Abstract
Genome-wide association scans provide the first successful method to identify genetic variation contributing to risk
for common complex disease. Progress in identifying genes associated with melanoma show complex relationships
between genes for pigmentation and the development of melanoma. Novel risk loci account for only a small
fraction of the genetic variation contributing to this and many other diseases. Large meta-analyses find additional
variants, but there is current debate about the contribution of common polymorphisms, rare polymorphisms or
mutations to disease risk.
Background
Genome-wide association (GWA) methods have made
great progress in the last few years mapping genetic var-
iants contributing to risk for many common complex
diseases [1-3]. These methods developed from spectacu-
lar advances in genotyping technology, greater under-
standing of the structure of common variation in the
human genome, and continued advances in computing
power and software tools. Human populations have 10
to 15 million common single nucleotide polymorphisms
(SNPs). Analysis of patterns of SNP variation in the
human genome [4] demonstrate that a representative set
of 500,000 to 1,000,000 “tagging” SNPs can sample most
common variation. Current commercial SNP chips can
now screen genome-wide “tagging” SNPs in a single
experiment and provide an effective approach to search
for genetic variants contributing to the aetiology of
complex diseases.
Results and discussion
Pigmentation and melanoma
One example of mapping genes for related phenotypes
is the field of pigmentation and melanoma. Melanomas
([MIM 155600]) are malignant tumours of melanocytes
and susceptibility is influenced by complex relationships
between genetic and environmental factors [5,6]. Risk
factors include skin pigmentation (skin colour and tan-
ning response or phototype) and the numbers of
acquired melanocytic nevi or moles on the skin [5,6].
These intermediate phenotypes interact with the key
environmental factor, exposure to ultraviolet light.
The incidence of malignant melanoma in Caucasian
populations has increased substantially over the last 20
years [6] probably as a result of long-term changes in
sunexposure.
A number of GWA studies have been conducted
recently to improve our understanding of the genetics of
pigmentation and contributions to melanoma risk
[7-13]. Most studies have been conducted in Caucasian
populations and it is important to note that variants in
several pigmentation genes show significant differences
in frequency, and are responsible for differences in pig-
mentation between ethnic groups. Therefore, care must
be taken to avoid problems of population stratification
in the design and interpretation of studies on pigmenta-
tion and melanoma risk.
GWA studies have identified both known and novel
pigmentation genes and results have been replicated and
extended by further studies including a recent meta-ana-
lysis [14]. Genes controlling pigmentation and tanning
response include ASIP [MIM 600201], IRF4 [MIM
601900], KTLG [], MC1R [MIM 155555], OCA2 [MIM
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609802], SLC24A4 [MIM 609840], TYR [MIM 606033],
TYRP1 [MIM 115501]. Variants in or near genes ASIP,
KTLG, MC1R, OCA2, IRF4, SLC24A4, SLC45A2,a l s o
affect sun sensitivity and/or melanoma risk [14].
In some cases the variants are located within coding
regions and have functional consequences [15]. How-
ever, most variants will not be causal and the association
is a consequence of linkage disequilibrium between the
marker and the causal variant(s). For example, OCA2
has long been implicated as an important gene affecting
blue/brown eye color. Genetic analysis of SNPs in the
gene HERC2 which lies upstream from OCA2 (in the
direction of transcription for OCA2)i d e n t i f i e das i n g l e
SNP rs12913832 in intron 86 of HERC2 accounting for
most of the variation in blue/brown eye colour [16,17].
This SNP lies in the centre of a short highly conserved
sequence which forms a consensus binding site for the
helicase-like transcription factor (HLTF) and is likely to
control constitutive expression of OCA2[17]. This and
other examples demonstrate that causal variants may lie
in flanking genes. In regions of association where multi-
ple genes may influence risk of melanoma or other dis-
eases, additional studies will be necessary to determine
the likely causal variant(s) and define the gene or genes
responsible for the phenotypic effect.
Moles and melanoma risk
The most important risk factor for melanoma is the
number of acquired moles [5]. Depending on the popu-
lation under study, the risk for melanoma increases by
2%–4% for each additional mole counted and individuals
in the top 10% of the mole count distribution have a 5-
to 10- fold higher risk. Sun exposure interacts with both
pigmentation and development of moles, but there is
evidence for “divergent pathways” for the roles of UV
radiation exposure and high mole count in development
of melanoma (Whiteman 2003). Individuals with lower
melanocyte proliferation and few moles develop mela-
noma on body sites with high cumulative UV radiation
exposure while those with high melanocyte proliferation
develop melanoma on body sites with lower UV radia-
tion exposure and more moles. Total mole count has a
high heritability of ~70% [18,19] and about half the
genetic variance for mole count can be attributed to a
locus in the region of CDKN2A (MIM 600160) on chro-
mosome 9 [9,18,19]. High-penetrance coding mutations
in CDKN2A are reported in families with multiple mela-
noma cases and these families also carry greater num-
bers of nevi. However, the CDKN2A variants exist at
population frequencies of less than 0.1%, and so explain
no more than 1%–2% of melanomas in the general
population. A GWA study of mole count identified
common SNPs in MTAP (MIM 156540) associated both
with mole count and melanoma risk [9]. MTAP is
located adjacent to CDKN2A on chromosome 9p and it
is not known whether the risk alleles in the 5’ region of
MTAP act through direct effects on MTAP or through
effects on CDKN2A. The same study also demonstrated
association with mole count and melanoma risk for a
second locus on chromosome 22q13. The strongest
association signal was for a SNP in the second intron of
PLA2G6, a gene belonging to the phospholipase A2
(PLA2) super family of genes [9].
The gene IRF4 is also associated with mole count, but
shows a strong gene x age interaction [20]. The T allele
for rs12203592 located in intron 4 of IRF4 was asso-
ciated with high mole counts and high freckling scores
in adolescents, but with low mole counts and high
freckling scores in adults. The C allele (associated with
higher mole count in adults) was also associated with
melanoma risk, most significantly with melanoma on
the trunk. The gene x age interaction could easily have
been missed in a single sample combining individuals of
different age groups.
GWA studies have made good progress in identifying
genes contributing to variation in pigmentation, mole
development and melanoma risk. It is estimated that
variants so far identified for genes influencing skin, eye
and hair colour and tanning response account for about
half of the melanoma risk due to pigmentation [21]. In
contrast, only 2% of variation has been explained for
non-pigmentation factors associated with melanoma risk
including mole count. However, many of these effects
are likely to act through melanocytes and CDKN2A,
implicated directly in mole development and melanoma
risk, has associated pigmentation effects in chickens
[22]. Missense mutations in the coding region of
CDKN2A are responsible for sex-linked barring, a com-
mon plumage colour characterized by black and white
barred feathers. These studies illustrate the complex
relationships between genes and environment in pig-
mentation and the development of melanoma.
Effect size and missing variation
GWA methods have been very successful in identifying
genes and variants associated with common diseases
and these discoveries have provided new insights into
the biology of many diseases. However, the effect sizes
for individual variants are generally small with odds
ratios for the risk alleles in the range of ~1.1 to ~1.5.
Pigmentation variation has been under strong selection
and there are large effects reported for some individual
variants. In contrast, the effects of variants associated
with melanoma risk are more modest and typical of
effect sizes for variants associated with most common
diseases. Collectively, known variants for individual dis-
eases only account for a small fraction of the familial
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has been to combine results from many studies and
conduct meta-analysis of results with sample sizes of
over 100,000 individuals. This approach is only possible
for diseases or phenotypes where many samples have
been collected with the same or similar disease defini-
tions. Some recent examples include the analysis of
smoking behavior in 74,000 individuals [23], and serum
lipids in >100,000 individuals [24]. These large studies
have greatly increased power and each identify many
novel associated variants. However, in most cases the
combined results still only explain a small proportion of
the genetic variation. There has been much debate
about the source of the other “missing” variation. The
two main possibilities are that most causal variants are
not tagged well by SNPs on commercial chips (e.g.
because they occur at lower frequency or are in areas of
the genome for which it is difficult to develop SNP
assays), or genetic contributions to disease risk are due
to many variants with odds ratios so small that they do
not reach formal statistical significance despite large
GWA studies. Current commercial SNP chips generally
target common variants. Ability to tag causal variants
depends on linkage disequilibrium, in turn influenced by
differences in allele frequency between markers and low
frequency or rare variants will not be well “tagged” by
SNP markers on many current chips.
Contribution of rare variants
Contribution to disease risk in the population is a func-
tion of allele frequency and also of effect size for the
risk allele. Rare disease associated variants not tagged by
current chips can only be the source of missing herit-
ability if the risk alleles have large effects. Re-sequencing
of genomic regions uncovers new variation and there
are a number of examples where rare variants contribute
to risk for common traits. Rare variants in CDKN2A
discussed above contribute to melanoma in high risk
families, but explain little of the population prevalence
for this disease. GDF9 is expressed in human oocytes
and plays important roles in growth and selection of
ovarian follicles. A search for GDF9 variants in mothers
of spontaneous DZ twins identified three novel deletions
and four mis-sense alterations [25,26]. Taken together,
the frequency GDF9 variants were significantly higher in
mothers of DZ twins compared with controls [25,26].
However, the frequency of the variants is low (less than
4% for all variants) and the contribution of these var-
iants to the overall incidence of twinning is small. Rese-
quencing a candidate gene for type 1 diabetes detected
new variants at ~1% frequency that in total contributed
more to variation in risk in the population than a single
common variant in the same gene detected by a pre-
vious GWA study [27]. Recently, GWA identified
common variants APOA5, GCKR, LPL and APOB asso-
ciated with hypertriglyceridemia (HTG, [28]). Resequen-
cing of these genes revealed a significantly higher
burden of rare missense or nonsense variants in indivi-
duals with HTG, compared to controls corresponding to
a carrier frequency of 28.1% of affected individuals and
15.3% of controls. Common genetic variants in seven
HTG-associated loci explained ~20% of total variation
in HTG diagnosis, and the rare genetic variants in four
HTG-associated loci explained ~1% of variation. There-
fore, both rare and common variants in the same genes
can influence disease risk. Based on current examples,
the contributions from rare or low frequency variants
are similar to common variants and much variation in
genetic contributions to disease risk is still “missing”.
Common variants of small effect explain missing
heritability
Most GWA studies have examined evidence for associa-
tion SNP by SNP. An alternative approach is to analyse
data for all SNPs together to estimate the proportion of
trait variance accounted for by all common variation
“tagged” by the SNPs on current commercial SNP chips.
This is possible because the distant genetic relatedness
of individuals can be estimated from dense SNP data.
Once the degree of relatedness is established, it can be
compared to phenotypic similarity between the indivi-
duals. This method was developed and used to estimate
the genetic contribution to variation in height indepen-
dent of the usual assumptions required to estimate her-
itability using family data [29]. Using this approach, the
percentage of phenotypic variation explained by com-
mon SNPs was 45%.
This is less than the 80% of phenotypic variance due
to additive genetic effects based on the estimated herit-
ability. However, the SNPs sampled on the arrays may
not be in complete LD with the causal variants and this
might influence the results. If the estimate is corrected
first for the sampling error from using a finite number
of SNPs with genotype data, the corrected estimate for
variance explained by causal variants is 54% (assuming
the same structure of linkage disequilibrium between
causal variants and common SNPs sampled on the
arrays). In addition, if the causal variants tend to have
lower minor allele frequencies than SNPs on the arrays,
we would expect lower LD between genotyped SNPs
and causal variants [29]. When this is taken into
account, the estimated contribution of phenotypic varia-
tion explained was 84%. The standard error for this esti-
mate is large and it does not prove that causal variants
do have lower allele frequencies than tagging SNPs used
on the chips. However, if this were the case, most of the
phenotypic variation in height due to additive genetic
effects could be explained by many common variants
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human height or more generally remains to be seen.
Conclusions
GWA studies have identified a large number of variants
associated with a range of human traits and common
diseases. However, the sizes of effects on disease risk are
typically small. Combining results across many studies
increases the power to detect risk variants and rese-
quencing is uncovering rare variants with modest con-
tributions to a number of diseases. The emerging view
from all these studies is a spectrum of many variants
with small effects explaining genetic contributions to
disease risk.
The discoveries provide new insights into the biology
of many diseases with a number of variants located in
genes that contribute to biological pathways not pre-
viously considered to be involved in disease, or located
in regions that do not contain known protein-coding
genes. Some examples like the effects of IRF4 on mole
count show interactions that would reduce estimated
effects size from large combined studies. Therefore one
important outcome of GWA studies will be to use
knowledge gained to evaluate genetic contributions to
disease sub-classes, disease heterogeneity and co-mor-
bidity for different diseases. The next challenge is how
to translate these discoveries into better diagnostic prac-
tices, preventions and treatments.
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